Quantcast

Latest H5N1 clinical trials Stories

2011-02-23 06:00:00

ATLANTA, Feb. 23, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) announced today the publication of the results of Phase 1 clinical trial testing of its HIV/AIDS vaccine products. The article, titled "Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles," will appear in the March 1 issue of The Journal of Infectious Diseases. A PDF of the article is available at the following URL:...

2011-02-18 15:27:07

Nasal spray vs. injection -- what would you prefer? Adelaide researchers have taken a step closer to the development of a universal flu vaccine, with results of a recent study showing that a vaccine delivered by a simple nasal spray could provide protection against influenza. University of Adelaide researcher Dr Darren Miller and colleagues have successfully trialled a synthetic universal flu vaccine in mice. The results have appeared this month in a paper in the Journal of General Virology....

2011-02-18 07:00:00

ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting (WHO) on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting was held at the WHO headquarters in Geneva, Switzerland where Dr. Gregory...

2011-02-15 06:00:00

QUEBEC CITY, Feb. 15 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Ms. Nathalie Landry, Vice President of Product Development, is invited to present at the 7(th) WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. The conference is being held at the World...

2011-02-08 07:44:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, Feb. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the...

ec9237a66a1e987e191d312538652c70
2011-02-01 13:43:15

The World Health Organization (WHO) is reviewing the safety of GlaxoSmithKline's Pandemrix H1N1 flu vaccine after a Finnish study suggested children who got the shot were nine times more likely to suffer from narcolepsy. The rare sleeping disorder causes a person to fall asleep suddenly and unexpectedly Its cause is not understood but it is generally consider to be triggered by a combination of genetic and environmental factors. Researchers at Finland's National Institute for Health and...

2011-02-01 06:19:00

- Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - -Company's VLP induced the production of antibodies that cross react with multiple strains of influenza- QUEBEC CITY, Feb. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results...

2011-01-27 06:00:00

PRINCETON, N.J., Jan. 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures. The technology is the subject of several United States and foreign patent applications...

2011-01-15 00:00:41

The Phase 2a clinical trial for HIV/AIDS vaccine has now expanded from 225 to 300 participants (Vocus/PRWEB) January 13, 2011 GeoVax Labs, Inc. recently announced the expansion of the Phase 2a clinical trial testing of its HIV/AIDS vaccine products. The expanded Phase 2a trial will test the administration of three doses of the recombinant poxvirus vaccine MVA62B without the use of the recombinant DNA-vectored vaccine, which was used to prime immune responses in the first part of this trial....

2011-01-07 07:21:16

(Ivanhoe Newswire) -- Two doses of the chickenpox vaccine provide excellent protection in children against the highly-contagious itchy disease, according to a new study. The Centers for Disease Control and Prevention (CDC) began recommending a single dose of chickenpox vaccine in children aged 1 to 13 years old in 1995. Although the incidence of chickenpox fell by 90 percent after introduction of the vaccine, there was a high rate of breakthrough chickenpox illness in immunized children and...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related